drugset / Trial / NCT04189614
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Timeline
- Start
- 2020-02-13
- Primary completion
- 2026-05-07
- Completion
- 2026-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cofetuzumab Pelidotin | Other / unclassified | 2.8 mg/kg | Intravenous |